Cytokinetics, Incorporated

Good afternoon and welcome, ladies and gentlemen, to the Cytokinetics second quarter 2020 conference call. At this time, I'd like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company's request, we will open the call for questions and answers after the presentation. I would now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.

Good afternoon and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will kick off the call with an overview of the quarter and our recent progress. Then, Fady Malik, our EVP of Research and Development, will provide updates on key developments for Omecampt and McCarbell, our cardiac niacin activator being developed under our collaboration with Amgen, and the expanded and accelerated development plan for CK274, are next in class cardiac myosin inhibitor. Next, Stuart Kupfer, our SVP and Chief Medical Officer, will update on recent progress with CK274 in Redwood HCM, as well as CK274, our additional cardiac myosin inhibitor. Then Robert Wong, our VP and Chief Accounting Officer, will provide an overview of the quarter, and Ching Jha, our SVP and Chief Financial Officer, will discuss our updated financial guidance in the context of recent corporate development activities before Robert Blum provides concluding thoughts on the company's outlook and expected key milestones for the remainder of the year. Please note that portions of the following discussion, including our responses to questions, contain statements that relate to future events and performance rather than historical facts and constitute forward-looking statements. Our actual results might differ materially from those projected in these forward-looking statements. additional information concerning factors that could cause our actual results to differ materially from those in these forward-looking statements is contained in our SEC filings. We undertake no obligation to update any forward-looking statements after this call. And now I will turn the call over to Robert.

Thank you, Diane. And thanks again to everyone for joining us on the call today. It was a productive second quarter and the momentum continues into this third quarter. Many of you have had the opportunity to participate in calls relating to our licensing collaboration and royalty monetization transactions followed by our investor and analyst day event last month. We shared a lot of information on those calls just a few weeks ago, so we'll try not to be too repetitive today. There's no doubt that this is truly a transformative time in our company's maturation, and I couldn't be more proud of the high level of strategic execution demonstrated by our leadership team. The combination of licensing, royalty monetization, and equity capital market deals we transacted fortifies our expected cash balance sheet at year-end to over $500 million and ensures our strong financial position as we approach top-line results of Galactic HF, one of the largest Phase III global cardiovascular outcomes trials in heart failure. which is being conducted by Amgen under our long-standing collaboration. These deals, considered alongside our previously announced renegotiation of our ASTELLAS agreement, enables us to continue readiness and implementation activities related to the potential commercialization of Omicampt and McCarble as well as concurrently plan for the advancement of CK274 and REL Deceptive all within the context of our vision 2025. In addition to having the opportunity to co-commercialize Omicampt and McCarble in partnership with Amgen, these recent deals enable us to continue to control the development of CK274 and real deceptive to an expanded set of pivotal clinical trials while retaining full rights in North America, Europe, and Japan for our shareholders. It's particularly gratifying when our R&D strategies can synchronize with and enable the corporate development and business development strategy. Tokinetics continues to leverage our innovative science through partnerships to maximize opportunities across the breadth and depth of our pipeline of investigational medicines focused to muscle biology. And with that, I'll turn the call over to Fady collaborate on key developments for Omicampt and McCarble and CK274.